Back

Proton pump inhibitors in myocardial infarction: safety paradox in Type 1 vs. Type 2---a multicenter retrospective cohort study

1 September 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Post-myocardial infarction management Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jiayi Ren

2nd Hospital of Tianjin Medical University, Tianjin (China)

5 More presentations in this session

Presentation thumbnail
Beta-blockers improved cardiovascular outcome in AMI patients with severe heart failure: a multi-center real-world study
Doctor R. Guo (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Beta-blocker duration and long-term cardiovascular risk after myocardial infarction with reduced ejection fraction
Doctor S. Fang (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
Antithrombotic therapy in patients with takotsubo cardiomyopathy: is heparin associated with lower mortality? - a nationwide cohort analysis
Doctor S. Hijikata (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial
Professor M. Shechter (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
Associate Professor M. Cavender (Chapel Hill, US)
Abstract Slides

Access the full session

Session thumbnail
Post-myocardial infarction management

The Event

Event poster

ESC Congress 2025

1 September 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Association between reduced risk of gastrointestinal bleeding related to proton pump inhibitor use and subsequent all-cause death in patients with percutaneous coronary intervention
thumbnail
Congress Presentation
Safety and effectiveness of tegoprazan in patients treated with dual antiplatelet therapy after drug-eluting stent implantation for acute myocardial infarction.
thumbnail
Congress Presentation
Incidence and outcomes of new and persistent use of proton pump inhibitors following percutaneous coronary intervention: a retrospective population-based study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources